BBIO Stock Forecast & Price Target

BridgeBio Pharma's financial outlook is strengthened by a projected revenue increase, with full-year 2026 revenue forecasts rising to $766.3 million, reflecting confidence in the company's late-stage pipeline and robust sales of its lead product, Attruby (acoramidis). The accelerating adoption of Attruby, alongside highly positive clinical data for additional candidates such as ribitol and encaleret, positions the company for significant revenue generation and potential regulatory approvals in the near term. Furthermore, the increasing number of unique patient prescriptions for Attruby suggests a strong market demand and a favorable trajectory for the company's offerings in the genetic disease treatment space.

BridgeBio Pharma faces a negative outlook largely due to a projected net loss of $3.59 billion for full-year 2025, compounded by a quarterly net loss of $182.7 million which exceeded expectations. The company's limited cash reserves and substantial debt pose significant financial risks, making it challenging to sustain operations in the event of clinical setbacks or failures in its late-stage pipeline programs. Additionally, competitive pressures and potential patent issues related to existing treatments, such as tafamidis, could hinder the company’s ability to penetrate key markets effectively, further impacting its financial health.